All Oncology News

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

Bernard H. Bochner, MD, FACS, discusses considerations for community oncologists when treating patients with muscle-invasive bladder cancer.

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

The FDA's Medical Imaging Drugs Advisory Committee voted 16 to 2 in support of the benefit-risk profile of Lumisight.

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.

PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.

Racial and ethnic disparities for mortality are present in breast cancer, especially as it relates to radiation therapy toxicity and cardiac dose.

Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.

Although immune checkpoint inhibitors can yield dramatic results and give some patients many years of life, some patients do not yield benefit.

Cambritaxestat has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

Trastuzumab deruxtecan has significant intracranial activity in patients with HER2-positive breast cancer brain metastases, regardless of subgroup.

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for select patients with relapsed/refractory follicular lymphoma.

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

Eftilagimod alpha in combination with chemotherapy displayed a manageable safety profile in HR+/HER2-low breast cancer.

The FDA has approved nivolumab plus cisplatin and gemcitabine for first-line use in adult patients with unresectable or metastatic urothelial carcinoma.

Survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.

Belantamab mafodotin plus pomalidomide and dexamethasone extended PFS in relapsed/refractory multiple myeloma.

PARP inhibitors have shown promise in ovarian cancer treatment, but certain subgroups of patients have few effective options following disease progression.

Patients with upper tract urothelial cancer who received adjuvant chemotherapy after nephroureterectomy experienced extended DFS vs those who received surveillance.

The FDA has approved inotuzumab ozogamicin for pediatric patients with relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss enrollment to the ECLIPSE trial in community and academic cancer center settings.